|
Bryce D. Carmine was named president global brand development teams in March 2005. He also is a member of the company's operations committee and the senior management council. Prior to moving to his new position Carmine had been president of metabolic disorders and specialty products since May 2004.
Born in New Zealand he received a bachelor of science in biochemistry from Massey University in 1973.
Carmine joined Lilly in 1975 as a sales representative in New Zealand and subsequently held several marketing and management positions in New Zealand before moving in 1983 to corporate headquarters in Indianapolis as advisor in international marketing development. In 1986 he was named general manager of Daewoong-Lilly Pharmaceutical Company in Seoul Korea a joint venture between Lilly and Daewoong.
He became managing director of Lilly operations in Australia in 1989 and concurrently the chairman of AZA (Lilly/Carvan Research Institute joint venture) from its inception. During his tenure in Australia he was actively involved in the Australian Pharmaceutical Research and Manufacturers Association holding the position of chairman from 1992 to 1995. Carmine served as the president and general manager of Eli Lilly Japan from 1995 to June 1999.
Commensurate with his responsibility Carmine is chairman of the Lilly ICOS joint venture (a collaboration that developed Cialis® an investigational PDE5 inhibitor in development for the treatment of erectile dysfunction. Additionally he is co-chairman of the Lilly/Boehringer Ingelheim steering committee a joint project to develop and market Cymbalta for depression and its related product for stress urinary incontinence. | 